Luis G Carvajal‐Carmona
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (41)
Latin America’s population is among the most genetically diverse in the world, shaped by centuries of European colonization, Indigenous American displacement, and forced African slave migration. This complex ancestry, combined with persistent social inequalities, influences cancer risk through both genetic and environmental factors. For example, Indigenous ancestry has been linked to a lower risk of breast cancer, a protective effect further influenced by reproductive patterns and access to healthcare. In this issue, Pinto and colleagues trace the history of the TP53 p.R337H founder variant, a mutation now present in about 1 in 300 people in southern Brazil. Their analysis shows that this variant was introduced during early Portuguese colonization and spread throughout Brazil as the population grew rapidly. This story highlights how historical events continue to shape cancer risk today. Founder mutations, such as TP53 p.R337H, are common across Latin America and often trace to Iberian ancestors. These variants offer unique opportunities for low-cost genetic screening and precision medicine, especially in regions with limited resources. They also serve as natural experiments for studying how genes and the environment interact to influence cancer risk. By understanding and leveraging these genetic legacies, we can enhance cancer prevention and treatment in Latin America, reduce disparities, and gain valuable insights to address global cancer health. See related article by Pinto et al., p. 210
Year:
2026
Breast cancer (BC) is a heterogeneous disease, and triple-negative breast cancer (TNBC) is the most aggressive and immunogenic subtype. A significant proportion of TNBC cases are linked to hereditary cancer syndromes involving pathogenic germline variants, most commonly in BRCA1/2. However, few studies have compared hereditary and sporadic TNBC in admixed populations. In this study, molecular and immunological features were analyzed through the analysis of 62 Colombian TNBC samples (20 hereditary and 42 sporadic cases) by RNA sequencing to identify molecular and immune differences. We used an external validation cohort of 16 TCGA TNBC cases (8 BRCA-mutated and 8 non-mutated) to replicate our findings. Results: We found a set of 921 differentially expressed genes (DEGs) between hereditary and sporadic TNBC. Hereditary tumors were enriched for pathways related to extracellular matrix (ECM) remodeling, structural components, and DNA damage response and exhibited a more immunologically active tumor microenvironment compared to sporadic tumors. LASSO logistic regression identified 23 genes with discriminatory potential, showing that hereditary tumors are characterized by complex immune regulation, inflammatory processes, and activation of key oncogenic pathways. Conclusions: Hereditary TNBC is characterized by molecular and biological functions linked to ECM remodeling and its constituents and an active immune microenvironment. This integrated molecular–immune profile provides insight into the distinct biology of hereditary tumors in admixed populations.
Year:
2025
Genetic studies in Latin America have expanded, but further efforts are needed to understand cancer susceptibility genes beyond BRCA1 and BRCA2 , especially by characterizing the prevalence and spectrum of pathogenic or likely pathogenic variants (PVs) in the region. This study aimed to determine the frequency of hereditary cancer syndromes (HCS) in Colombians with solid tumors and to characterize the spectrum of PVs. Using data from the Colombia’s largest Institutional Hereditary Cancer Program, we included patients aged ≥18 years with solid tumors who met HCS criteria and were offered genetic testing with a 105-cancer gene panel. We calculated the prevalence of PVs and HCS by cancer type (beyond breast) and gene. For patients with breast cancer, we examined genotype-phenotype correlations with molecular subtypes and stratified positivity rates by different genetic testing criteria. Among 769 patients, we identified 216 PVs in 43 genes in 197 patients (26%). Thirty-three PVs were recurrent. Autosomal HCS was found in 21% (160/769) of patients (159 dominant, one recessive), while 5% (37/769) were heterozygous carriers of PVs in autosomal recessive genes. In 42% (321/769) of the cases, only one or more variants of uncertain significance (VUS) were identified, whereas 33% (251/769) had neither PVs nor VUS detected (negative results). HCS prevalence varied by cancer type (11–26%). The triple-negative subtype and bilateral presentation were strong predictors of inherited breast cancer. Our study reveals a significant presence of PVs among high-risk Colombian patients with solid tumors, underscoring the importance of genetic counseling and testing in the region.
Year:
2025
Background: A substantial portion of the genetic predisposition for breast cancer is explained by multiple common genetic variants of relatively small effect. A subset of these variants, which have been identified mostly in individuals of European (EUR) and Asian ancestries, have been combined to construct a polygenic risk score (PRS) to predict breast cancer risk, but the prediction accuracy of existing PRSs in Hispanic/Latinx individuals (H/L) remain relatively low. We assessed the performance of several existing PRS panels with and without addition of H/L-specific variants among self-reported H/L women. Methods: PRS performance was evaluated using multivariable logistic regression and the area under the ROC curve. Results: Both EUR and Asian PRSs performed worse in H/L samples compared with original reports. The best EUR PRS performed better than the best Asian PRS in pooled H/L samples. EUR PRSs had decreased performance with increasing Indigenous American (IA) ancestry, while Asian PRSs had increased performance with increasing IA ancestry. The addition of two H/L SNPs increased performance for all PRSs, most notably in the samples with high IA ancestry, and did not impact the performance of PRSs in individuals with lower IA ancestry. Conclusions: A single PRS that incorporates risk variants relevant to the multiple ancestral components of individuals from Latin America, instead of a set of ancestry-specific panels, could be used in clinical practice. Impact: The results highlight the importance of population-specific discovery and suggest a straightforward approach to integrate ancestry-specific variants into PRSs for clinical application.
Year:
2025
Ancestral estimates 1000Genomes individuals (n=929) not used in reference panel generation. Estimates calculated from 1000Genomes K=10 admixture data, SNPWeights Panel, and the differences between these estimates for each individual.
Year:
2024
Figure S1 shows the Clustering of 1,990 non-admixed reference samples and 2,387 admixed samples(brown) individuals based on the first three principal components. Colors represent the continental ances
Year:
2024
1000Genomes K=10 Admixture Estimates downloaded from ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/admixture_files/ALL.wgs.phase3_shapeit2_filtered.20141217.maf0.05.10.Q. Super-population designations were added to the partitions by sorting each partition and determining the corresponding designation for each partition.
Year:
2024
PDXnet metadata for samples for which genetic ancestry was estimated and samples were assigned into African (AFR), European (EUR), East Asian (EAS), American (AMR), and South Asian (SAS) continental ancestry.
Year:
2024
PDXnet metadata for samples for which genetic ancestry was estimated and samples were assigned into African (AFR), European (EUR), East Asian (EAS), American (AMR), and South Asian (SAS) continental ancestry.
Year:
2024
1000Genomes K=10 Admixture Estimates downloaded from ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/admixture_files/ALL.wgs.phase3_shapeit2_filtered.20141217.maf0.05.10.Q. Super-population designations were added to the partitions by sorting each partition and determining the corresponding designation for each partition.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (43)
Lawrence Rubinstein
Statistician
National Cancer Institute
Matthew H Bailey
Assistant Professor
Brigham Young University
Jose G. Trevino
Virginia Commonwealth University
Katherine Chiu
University of California, Davis
Christopher A. Haiman
University of Southern California
Laura Fejerman
Professor
University of California, Davis
Michael A. Davies
-
Sherri Davies
Senior Scientist
Washington University in St. Louis
FEI CHEN
Assistant Professor
University of Southern California
Min Jin Ha
Assistant Professor
The University of Texas MD Anderson Cancer Center
Lisa McShane
Associate Director, Division of Cancer Treatment & Diagnosis
National Cancer Institute
Peter Robinson
Professor for Medical Computer Science
The Jackson Laboratory for Genomic Medicine
Jeffrey Chuang
Jackson Laboratory
Weang Kee Ho
Professor
Sunway University
Bizu Gelaye
Chief, Epidemiology Branch and Senior Investigator
Eunice Kennedy Shriver National Institute of Child Health and Human Development
I. King Jordan
Professor
Georgia Institute of Technology
Xiaowei Xu
Professor
University of Pennsylvania
Shidan Wang
-
Junya Fujimoto
Professor and Chair
Hiroshima University Hospital
Alana Welm
Chair
Huntsman Cancer Institute
Nicholas Mitsiades
Professor
University of California, Davis
Bryan Welm
Associate Professor
Huntsman Cancer Institute
Elad Ziv
Professor
University of California
Meenhard Herlyn
Professor, Director
The Wistar Institute
Xuelin Huang
Professor
The University of Texas MD Anderson Cancer Center
Esther John
Professor
Stanford University School of Medicine
Shunqiang Li
Associate Professor
Washington University in St. Louis
Jing Wang
Professor
The University of Texas MD Anderson Cancer Center
Ryan C. Fields
University of Rochester
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Robert Mashl
Washington University in St. Louis
Chong-xian Pan
Professor
university of california davis medical center
Carol Bult
Professor and Knowlton Family Chair
Jackson Laboratory
David Conti
Professor
Colorado School of Public Health
Salma Kaochar
Assistant Professor
Baylor College of Medicine
Li Ding
Associate Professor
Washington University in Saint Louis School of Medicine
Michelle Williams
Professor of Epidemiology
Stanford University
J. Chuck Harrell
Virginia Commonwealth University
Michael Lewis
Baylor College of Medicine
Maria Gabriela Raso
Assistant Professor
The University of Texas MD Anderson Cancer Center
Soner Koc
GlaxoSmithKline Research and Development
Guanghua Xiao
-
Yang Xie
Professor
University of Texas Southwestern Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.